Lanthanum carbonate is a new nonaluminium, noncalcium phosphate binder. The drug is well-tolerated its side-effects seem comparable to those of other phosphate binders. The most frequent side-effects are gastrointestinal complications. Cerny [New England Journal of Medecine 355(2006)1160.] and Kunzendorf have recently reported another effect of lanthanum carbonate based on its radiographic characteristics. We report another case of opacification of the intestine with lanthanum carbonate which underlines some difficulties in the use of this new phosphate binder.
Objective: To comprehensively investigate the efficacy and safety of lanthanum carbonate in conjugation with calcium carbonate combination in hemodialysis patients with hyperphosphatemia via a meta-analysis of randomized controlled trials (RCTs).
Method: We conducted a literature search in databases of PubMed, Embase, and Web of Science for RCTs investigating the effect of lanthanum carbonate in combination with calcium carbonate for treating hyperphosphatemia in hemodialysis patients. The search covered all studies from the inception of the database until October 2023.
Purpose: Phosphate binders (PB) are integral to hyperphosphatemia management in patients with end-stage kidney disease. PB efficacy is adversely affected by nonadherence and limited phosphate-binding capacity relative to dietary intake. Oxylanthanum carbonate is an investigational novel nanotechnology product that combines lanthanum, which has the highest binding capacity of available PBs, with a smaller pill size that is swallowed with water rather than chewed.
Molecular Cell Biology Laboratory, Department of Systems Engineering and Science, Graduate School of Engineering and Science, Shibaura Institute of Technology, Fukasaku 307, Minuma-ku, Saitama 337-8570, Japan.
The use of metal nanoparticles such as cerium oxide nanoparticles (nanoceria) in living organisms is attracting increasing attention. We administered nanoceria to chronic kidney disease model rats, including a 5/6 nephrectomy model and adenine administration model rats, and reported high phosphorus adsorption capacity and renal function improvement effects of nanoceria. However, the iron ion concentration in the serum fluctuated significantly after administration.
Up to 5% of patients with newly diagnosed celiac disease have negative serology. Although seronegative celiac, is the most common cause for villous atrophy, there are other differential diagnoses that should be ruled out when we find villous blunting without positive serology for celiac disease. The aetiologies are usually divided into 5 categories: immune-mediated, infectious, iatrogenic, inflammatory and infiltrative.
Electroplating wastewater containing high concentrations of phosphates and hexavalent chromium Cr(VI) poses serious environmental pollution. Moreover, phosphorus, as a non-renewable resource, necessitates its recovery to meet sustainable development goals. To address this issue, this study used sodium alginate as the scaffold module, synthesized lanthanum carbonate in situ within a chitosan module to serve as the phosphate adsorption module, and employed polyethyleneimine (PEI) modules to enhance the adsorption capacity for Cr(VI), successfully fabricating a modular hydrogel (LC-CSP).
